Showing 2861-2870 of 4166 results for "".
- CureVac and the University Medical Center Mainz Start Phase 3 Clinical Trial for COVID-19 Vaccine Candidatehttps://modernod.com/news/curevac-and-the-university-medical-center-mainz-start-phase-3-clinical-trial-for-covid-19-vaccine-candidate-cvncov-in-healthcare-workers/2478683/CureVac NV announced that the first participant in a clinical phase 3 study with its COVID-19 vaccine, CVnCoV, in healthcare workers at the University Medical Center Mainz will be vaccinated on December 22, 2020. The study aims to evaluate the safety and immunogenicity of CVnCoV administered as a
- CORE and Myopia Profile Form Alliance to Expand Clinical Research and Professional Education Capabilitieshttps://modernod.com/news/core-and-myopia-profile-form-alliance-to-expand-clinical-research-and-professional-education-capabilities/2478595/The Centre for Ocular Research & Education (CORE) and Myopia Profile announced an alliance designed to expand both organizations’ services and reach. The affiliation aims to grow CORE’s extensive clinical research capabilities, adding expertise in specialty lenses, gas permeable, orthokerato
- Innovent Announces the Results of the Phase 1 Clinical Trial of IBI302 for Wet AMD at AAO 2020https://modernod.com/news/innovent-announces-the-results-of-the-phase-1-clinical-trial-of-ibi302-for-wet-amd-at-aao-2020/2478560/Innovent Biologics announces that the results of the phase 1 clinical trial of IBI302, a first-in-class ophthalmic recombinant human anti-VEGF and anti-complement bi-specific fusion protein for wet age-related macular degeneration (AMD) is released in e-poster at 2020 American Academy of Ophthalm
- Oyster Point Pharma Announces Clinical Data Presentations on OC-01 Nasal Spray for Dry Eye Disease at AAO Virtualhttps://modernod.com/news/oyster-point-pharma-announces-clinical-data-presentations-on-oc-01-nasal-spray-for-dry-eye-disease-at-aao-virtual/2478548/Oyster Point Pharma announced new data from its phase 2 IMPERIAL clinical trial evaluating OC-01 (varenicline) nasal spray in the treatment of the signs and symptoms of dry eye disease in adults at the AAO 2020 Virtual Annual Meeting, being held on November 13-15. A single administration o
- Last Patient, Last Visit Completed in RegeneRx Phase 3 Dry Eye Clinical Trialhttps://modernod.com/news/last-patient-last-visit-completed-in-regenerx-phase-3-dry-eye-clinical-trial/2478508/RegeneRx Biopharmaceuticals announced that the final patient in its 700 subject, ARISE-3 phase 3 clinical trial for dry eye syndrome has completed treatment and follow-up. ARISE-3 is designed to assess the safety and efficacy of 0.1% RGN-259 eye drops compared to placebo after 2 weeks of
- PolyActiva Completes Initial Clinical Trial With Latanoprost FA SR Ocular Implant for 6-Month Glaucoma Treatmenthttps://modernod.com/news/polyactiva-completes-initial-clinical-trial-with-latanoprost-fa-sr-ocular-implant-for-6-month-glaucoma-treatment/2478494/PolyActiva announced it has successfully completed its phase I clinical study for its lead candidate, the Latanoprost FA SR Ocular Implant. The device was well tolerated in all 8 patients with no significant safety findings. The study also showed that the implant persists for the entire 6-
- Aerie Pharmaceuticals Initiates Phase 2b Clinical Trial of AR-15512 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aerie-pharmaceuticals-initiates-phase-2b-clinical-trial-of-ar-15512-trpm8-agonist-ophthalmic-solution-for-the-treatment-of-patients-with-dry-eye-disease/2478473/Aerie Pharmaceuticals announced the commencement of COMET-1, a phase 2b clinical trial of AR-15512 (TRPM8 agonist) ophthalmic solution for the treatment of patients with dry eye disease. The COMET-1 trial is a randomized, double-masked, vehicle-controlled trial evaluating the efficacy and
- Ocular Therapeutix Announces First Patients Dosed in Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Diseasehttps://modernod.com/news/ocular-therapeutix-announces-first-patients-dosed-in-phase-2-clinical-trial-of-otx-csi-for-the-treatment-of-dry-eye-disease/2478343/Ocular Therapeutix announced that it has dosed the first patients in its hase 2 clinical trial of OTX-CSI (cyclosporine intracanalicular insert) for the treatment of dry eye disease. “Having successfully completed the phase 1 study, we are excited to have recently begun dosing patients in
- Aurinia Completes Final Patient Treatment in AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for Dry Eyehttps://modernod.com/news/aurinia-completes-final-patient-treatment-in-audrey-phase-2-3-clinical-trial-of-voclosporin-ophthalmic-solution-for-dry-eye/2478336/Aurinia Pharmaceuticals announced that the last patient study visit has occurred in the phase 2/3 AUDREY clinical study evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES). “Despite the challenges posed by the ongoing viral pandemic, our c
- First Patient Dosed in Phase 3 Clinical Trial of Dextenza for the Treatment of Post-Surgical Ocular Inflammation and Pain in Childrenhttps://modernod.com/news/ocular-therapeutix-announces-first-patient-dosed-in-phase-3-clinical-trial-of-dextenza-for-the-treatment-of-post-surgical-ocular-inflammation-and-pain-in-children/2478274/Ocular Therapeutix announced that it has dosed the first patients in a phase 3 clinical trial of Dextenza (dexamethasone ophthalmic insert) 0.4 mg for the treatment of post-surgical ocular inflammation and pain in children following cataract surgery. “We are pleased to announce the start o